IVD Raw Material Market

The IVD raw material market is projected to grow from USD 21.5 billion in 2026 to USD 31.1 billion in 2031 at a CAGR of 7.7%. The increasing global prevalence of chronic and infectious diseases, along with the growing demand for accurate and early disease diagnosis, has underscored the critical role of high-quality raw materials in the development of in vitro diagnostic assays. The intersection of rising disease burden, expanding access to healthcare services, and heightened emphasis on preventive healthcare is driving demand for advanced IVD raw materials. Innovations in recombinant technologies, monoclonal antibody production, synthetic biology, and molecular biology are transforming the development and performance of diagnostic reagents used across clinical laboratory and point-of-care testing applications.

Regulatory emphasis on assay standardization, quality control, and diagnostic accuracy is driving the procurement of validated, high-performance raw materials, while the increasing integration of automation and digital technologies in diagnostic laboratories is accelerating demand for consistent, scalable reagent supplies. Furthermore, the growing adoption of molecular diagnostics, companion diagnostics, and personalized medicine is creating new opportunities for specialized IVD raw materials. Expansion potential in emerging economies across Asia Pacific, Latin America, and the Middle East, where diagnostic testing infrastructure continues to develop, presents a substantial incremental growth opportunity for participants in the IVD raw material market through 2031.

To know about the assumptions considered for the study download the pdf brochure

The prominent players in the IVD raw material market are Merck KGaA (Germany), Thermo Fisher Scientific (U.S.), Medix Biochemica (Finland), Bio-Techne (U.S.), and Fapon Biotech (China), among others. These companies have implemented a variety of growth strategies, both organic and inorganic, including new product launches, expansion of raw material portfolios, technological advancements in reagent development, and strategic acquisitions and partnerships. These initiatives aim to strengthen their positions in the global IVD raw material market, expand their geographic presence, and address the evolving requirements of diagnostic manufacturers.

For instance, in October 2024, Medix Biochemica launched new recombinant antibody and antigen solutions designed to support the development of next-generation immunodiagnostic assays, enhancing assay performance and supply chain reliability.

Similarly, in 2024, Thermo Fisher Scientific expanded its bioproduction and diagnostic reagent capabilities through investments in manufacturing infrastructure and strategic collaborations, enabling the company to better support the growing demand for high-quality raw materials for molecular diagnostics, immunoassays, and point-of-care testing. Such developments highlight the industry's focus on innovation, scalability, and quality assurance to meet the increasing demand for advanced IVD diagnostic solutions worldwide.

Merck KGaA has strengthened its position in the IVD raw material market through its extensive portfolio of high-quality biological and chemical reagents used in diagnostic assay development and manufacturing. The company serves a broad range of customers, including IVD manufacturers, biotechnology companies, and clinical diagnostic developers worldwide. Its leadership is supported by a comprehensive offering of antibodies, antigens, recombinant proteins, enzymes, buffers, and other critical raw materials that enable the development of immunodiagnostic, molecular diagnostic, and point-of-care testing solutions. Supported by strong research and development capabilities, global manufacturing infrastructure, and a focus on quality and regulatory compliance, Merck KGaA continues to enhance its competitive position and expand its presence across the global IVD raw material market.

Thermo Fisher Scientific is a leading participant in the IVD raw material market, supported by its extensive life sciences portfolio and strong global presence. The company offers a broad range of high-quality raw materials for diagnostic assay development, including antibodies, antigens, recombinant proteins, enzymes, nucleic acids, buffers, and other critical reagents for immunodiagnostics, molecular diagnostics, and point-of-care testing. Through its advanced research and development capabilities, robust manufacturing infrastructure, and stringent quality standards, Thermo Fisher Scientific enables diagnostic manufacturers to develop accurate, reliable, and high-performance diagnostic tests. Additionally, the company strengthens its competitive position through continuous product innovation, strategic collaborations, and global distribution networks, allowing it to effectively address the evolving needs of IVD manufacturers worldwide and maintain a strong position in the global IVD raw material market.

Market Ranking

Merck KGaA (through its Life Science business, operating as MilliporeSigma in the U.S. and Canada) has emerged as a leading participant in the IVD raw material market due to its extensive portfolio of antibodies, antigens, recombinant proteins, enzymes, and other critical diagnostic reagents. Thermo Fisher Scientific holds a significant position in the market owing to its broad range of life science products, diagnostic reagents, and bioproduction capabilities that support the development of immunodiagnostic, molecular diagnostic, and point-of-care testing assays. Medix Biochemica is a key player for its specialized expertise in developing and manufacturing high-quality antibodies, antigens, and assay components for diagnostic applications. Bio-Techne maintains a strong market presence through its extensive portfolio of proteins, antibodies, immunoassay reagents, and molecular diagnostic raw materials that enable the development of advanced diagnostic tests. Fapon Biotech is another major contributor to the market through its comprehensive range of antibodies, antigens, enzymes, and integrated raw-material solutions that support diagnostic manufacturers worldwide. Together, these companies continue to strengthen their market positions through product innovation, technological advancements, strategic investments, and expansion of their raw material portfolios, contributing to the growth and development of the global IVD raw material market.

Related Reports:

IVD Raw Material Market by Product Type (Proteins, Beads, Particles, Antibodies), Technology (Immunoassay, Hematology), Application (Infectious Disease, Diabetes), Supply Source, Origin (Biological, Synthetic), End User (CROs) - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]